| Outcome Measures: |
Primary: AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose, Measured in pmol\*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287., 0-840 hours|AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose, Measured in pmol\*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide., 0-840 hours | Secondary: AUCI287,0-∞ area under the serum insulin 287 concentration-time curve from 0 hours to infinity after a single dose, Measured in pmol\*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287., 0-840 hours|Cmax, I287, maximum observed serum insulin 287 concentration after a single dose, Measured in pmol/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287., 0-840 hours|tmax, I287, time to maximum observed serum insulin 287 concentration after a single dose, Measured in hour (h) for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287., 0-840 hours|AUCSema,0-∞, area under the plasma semaglutide concentration-time curve from 0 hours to infinity after a single dose, Measured in pmol\*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide., 0-840 hours|Cmax,Sema, maximum observed plasma semaglutide concentration after a single dose, Measured in pmol/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide., 0-840 hours|tmax,Sema, time to maximum observed plasma semaglutide concentration after a single dose, Measured in hour (h) for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide., 0-840 hours|Number of treatment emergent adverse events, Count of events., Day 1 (beginning of each period) to day 36 (end of each period)|Number of hypoglycaemic episodes, Count of episodes., Day 1 (beginning of each period) to day 36 (end of each period)|Antibodies for insulin 287: Change in anti-insulin 287 binding antibody levels, Measured as percentage B/T following administration of NNC0148 -0287sema and insulin 287., Day -1 (pre-dose), Day 36 (end of period)|Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies, Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287., Day 36 (end of period)|Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin, Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287., Day 36 (end of period)|Antibodies for semaglutide: Change in anti-semaglutide binding antibody levels, Measured as percentage B/T following administration of NNC0148 -0287sema, Day -1 (pre-dose), Day 36 (end of period)|Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies, Percentage of events (yes/no) following administration of NNC0148 -0287sema., Day 36 (end of period)|Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous glucagon-like peptide-1 (GLP-1), Percentage of events (yes/no) following administration of NNC0148 -0287sema., Day 36 (end of period)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-semaglutide binding antibody levels, Measured as percentage B/T., Day 151 (follow-up/end-of-trial visit)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous GLP-1, Percentage of events (yes/no)., Day 151 (follow-up/end-of-trial visit)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-insulin 287 binding antibody levels, Measured as percentage B/T., Day 151 (follow-up/end-of-trial visit)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin, Percentage of events (yes/no)., Day 151 (follow-up/end-of-trial visit)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies, Percentage of events (yes/no)., Day 151 (follow-up/end-of-trial visit)|Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1, Percentage of events (yes/no)., Day 151 (follow-up/end-of-trial visit)
|
